The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Equillium, Inc. COM 29446K106 575,233 1,824,977 SH DFND 1,824,977 0 0
Ovid Therapeutics, Inc. COM 690469101 1,897,500 5,750,000 SH DFND 5,750,000 0 0
Ovid Therapeutics, Inc. COM 690469101 587,880 1,781,996 SH SOLE 1,781,996 0 0
Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) COM 98422T100 1,002,935 1,475,121 SH DFND 1,475,121 0 0
Turnstone Biologics COM 90042W100 321,601 895,824 SH DFND 895,824 0 0
Shattuck Labs, Inc. COM 82024L103 408,267 515,619 SH DFND 515,619 0 0
Third Harmonic Bio, Inc. COM 88427A107 200,014 36,835 SH DFND 36,835 0 0
Lyell Immunopharma, Inc. COM 55083R104 363,906 41,165 SH DFND 41,165 0 0
Rani Therapeutics Holdings, Inc. COM 753018100 104,419 203,190 SH DFND 203,190 0 0
HilleVax, Inc. COM 43157M102 13,381,160 6,724,000 SH DFND 1 6,724,000 0 0
Standard Biotools, Inc. COM 34385P108 19,818 16,515 SH DFND 16,515 0 0
American Well Corporation COM 03044L204 691,050 77,733 SH DFND 77,733 0 0